| iTeos Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of a differentiated immuno-oncology therapeutics for patients. Co.'s product candidate, inupadenant, is designed as a selective small molecule antagonist of the adenosine A2a receptor, in the adenosine pathway, a main driver of immunosuppression in the tumor microenvironment across a range of tumors. Co.'s main antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains, an immune checkpoint with multiple mechanisms of action leading to immunosuppression. The ITOS average annual return since 2020 is shown above.
The Average Annual Return on the ITOS average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ITOS average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ITOS average annual return calculation with any dividends reinvested as applicable (on ex-dates).